Kymera Therapeutics (KYMR)
(Delayed Data from NSDQ)
$43.48 USD
+1.01 (2.38%)
Updated Jul 23, 2024 04:00 PM ET
After-Market: $43.49 +0.01 (0.02%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth A Momentum D VGM
Brokerage Reports
0 items in cart
Kymera Therapeutics, Inc. [KYMR]
Reports for Purchase
Showing records 1 - 20 ( 40 total )
Company: Kymera Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Kymera Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Kymera Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
EHA Data Continues to Support Potential for KT-333?s Degrader Approach
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Kymera Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Kymera Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Initial PoC Data of KT-253 Promising Given the MOA and the Landscape
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Kymera Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Encouraging Early Anti-Tumor Activity and Safety Data Supportive of KT-253?s Potential as Mono or Combination Therapies
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Kymera Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Kymera Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Durable Efficacy and Consistent Safety Profile at ASCO Important for KT-253
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Kymera Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Kymera Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Kymera?s KT-294 (TYK-2 Degrader) Continues to Build a Differentiated Narrative; Reiterate Buy and PT Up to $46
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Kymera Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Kymera?s KT-293 (TYK-2 Degrader) Continues to Build a Differentiated Narrative
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Kymera Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Newly Unveiled Immunology Programs Attractive for Potential Partnership Deals
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Kymera Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
PK, PD, and Safety Data Allow Wider Therapeutic Window for KT-333; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Kymera Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Optimized Entry and Exit Levels for KYMR 112123
Provider: Stock Traders Daily
Analyst: Research Department
Company: Kymera Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Initial PoC Data From STAT3 and MDM2 Programs Supports Further Development; Reiterate Buy and PT to $30
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Kymera Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
KT-253?s Superiority to SMIs Supports Degrader Approach to Target MDM2; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Kymera Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Expectations for KT-413?s ICML Data Readout; Reit. Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Kymera Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
KOL Call Invite: Getting Under the Skin in HS & PsA
Provider: Wedbush Securities Inc.
Analyst: ARGYRIDES A
Company: Kymera Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
KT-253 is an Ambitious Program with Potential for Broad Franchise Opportunities; Reit. Buy and $85 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Kymera Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Sanofi Puts Skin in the Game?Thoughts on KT-474 Data Readout
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A